BRPI0414688A - tratamento de doença respiratória com anti-receptor de il-2 - Google Patents

tratamento de doença respiratória com anti-receptor de il-2

Info

Publication number
BRPI0414688A
BRPI0414688A BRPI0414688-3A BRPI0414688A BRPI0414688A BR PI0414688 A BRPI0414688 A BR PI0414688A BR PI0414688 A BRPI0414688 A BR PI0414688A BR PI0414688 A BRPI0414688 A BR PI0414688A
Authority
BR
Brazil
Prior art keywords
receptor
respiratory disease
disease treatment
provides
antibody
Prior art date
Application number
BRPI0414688-3A
Other languages
English (en)
Inventor
Richard S Shames
Original Assignee
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pdl Biopharma Inc filed Critical Pdl Biopharma Inc
Publication of BRPI0414688A publication Critical patent/BRPI0414688A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

"TRATAMENTO DE DOENçA RESPIRATóRIA COM ANTICORPOS ANTIRECEPTOR DE IL-2". A presente invenção fornece um método de tratamento de doenças respiratórias. Em particular ela fornece um método de tratamento de asma que compreende a administração a um individuo de uma quantidade terapeuticamente eficaz de uma formulação farmacêutica que compreende um anticorpo, onde o referido anticorpo se liga ao receptor de IL-2.
BRPI0414688-3A 2003-09-23 2004-09-21 tratamento de doença respiratória com anti-receptor de il-2 BRPI0414688A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50588303P 2003-09-23 2003-09-23
US55297404P 2004-03-12 2004-03-12
PCT/US2004/031640 WO2005030252A1 (en) 2003-09-23 2004-09-21 Treatment of respiratory diseases with anti-il-2 receptor antibodies

Publications (1)

Publication Number Publication Date
BRPI0414688A true BRPI0414688A (pt) 2006-11-28

Family

ID=34396276

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414688-3A BRPI0414688A (pt) 2003-09-23 2004-09-21 tratamento de doença respiratória com anti-receptor de il-2

Country Status (8)

Country Link
US (1) US20050089517A1 (pt)
EP (1) EP1675615A1 (pt)
JP (1) JP2007506681A (pt)
AU (1) AU2004275860A1 (pt)
BR (1) BRPI0414688A (pt)
CA (1) CA2538737A1 (pt)
RU (1) RU2006113701A (pt)
WO (1) WO2005030252A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087991A1 (en) 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
TR201808152T4 (tr) 2008-05-28 2018-07-23 Prothera Biologics Inc Kandan inter-alfa inhibitör proteinlerinin hazırlanması ve bunların bileşimi.
AU2009325088B2 (en) * 2008-12-10 2014-06-19 Duke University Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
US9291626B2 (en) 2011-05-12 2016-03-22 Temple University—Of the Commonwealth System of Higher Education Diagnosis and treatment of chronic obstructive pulmonary disease (COPD)
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20190269765A1 (en) 2016-09-13 2019-09-05 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
BR112019011799B1 (pt) * 2016-12-13 2021-12-21 Delinia, Inc Proteína de fusão, proteína dimérica e composição farmacêutica
AU2018258466B2 (en) 2017-04-25 2025-05-22 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
EP3902584A4 (en) * 2018-12-29 2022-09-07 Kaleo, Inc. DEVICES AND METHODS FOR DELIVERING SUBSTANCES IN A PRE-FILLED SYRINGE
KR20220079576A (ko) * 2019-10-04 2022-06-13 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd25 항체-메이탄신 접합체 및 이의 사용 방법
US12268847B1 (en) 2021-02-10 2025-04-08 Kaleo, Inc. Devices and methods for delivery of substances within a medicament container
GB202106254D0 (en) * 2021-04-30 2021-06-16 Teva Uk Ltd Inhaler system
CN118370816A (zh) * 2024-03-22 2024-07-23 中日友好医院(中日友好临床医学研究所) Il-2/抗il-2抗体免疫复合物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473493A (en) * 1981-04-29 1984-09-25 Immunex Corporation Hybridoma antibody which inhibits interleukin 2 activity
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4845198A (en) * 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
BR9604978A (pt) * 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador com dose medida
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
DK1100829T3 (da) * 1998-07-27 2007-12-27 Novartis Ag Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme
WO2002081508A2 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
EP1578397B1 (en) * 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25

Also Published As

Publication number Publication date
JP2007506681A (ja) 2007-03-22
EP1675615A1 (en) 2006-07-05
WO2005030252A1 (en) 2005-04-07
AU2004275860A1 (en) 2005-04-07
CA2538737A1 (en) 2005-04-07
US20050089517A1 (en) 2005-04-28
RU2006113701A (ru) 2007-11-10

Similar Documents

Publication Publication Date Title
BRPI0410129A (pt) uso terapêutico de anticorpos anti-cs1
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
BRPI0412890A (pt) método de tratar uma doença em um indivìduo humano em necessidade do mesmo, composição farmacêutica, e, métodos de selecionar um composto para administração conjuntamente com um anticorpo terapêutico, e de aumentar a eficiência de um tratamento envolvendo a administração de um anticorpo terapêutico que pode ser ligado por cd16 em um indivìduo
EA030259B8 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
NO20051048L (no) Terapeutisk humant anti-IL-1R1 monoklonalt antistoff
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
CY1111812T1 (el) Ανθρωπινα εξουδετερωτικα αντι-ifn-γ αντισωματα ως εκλεκτικοι αναστολεις του μονοπατιου της ifn-γ
CY1118377T1 (el) Syk αναστολεις ιμιδαζοπυραζινης
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
BRPI0415195A (pt) anticorpos completamente humanos contra 4-1bb humana (cd137)
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
BRPI0416603A (pt) anticorpo que se liga ao receptor interleucina-4 (il-4) humano
EP2081435A4 (en) HAMMER OF BRUTON TYROSINE KINASE
MA31312B1 (fr) Anticorps anti-ige apoptopiques
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
BRPI0514124B8 (pt) anticorpos monoclonais específicos para il-4 humana, seu uso, composição farmacêutica que os comprende e polinucleotídeos
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
BRPI0407421A (pt) Terapia combinada para o tratamento de distúrbios imunoinflamatórios
TH84335A (th) แอนติบอดีของ dr5 และการใช้สิ่งนั้น

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.